Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR-8068 + axitinib
- Development stage
- Unknown
- Lead developer
- Suzhou Suncadia Biopharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
SHR-8068 + SHR-4610 is an investigational combination therapy being developed by Suzhou Suncadia Biopharmaceuticals, a subsidiary of Jiangsu Hengrui Pharmaceuticals, primarily for the treatment of advanced renal cell carcinoma (RCC). The regimen consists of SHR-8068, a fully human monoclonal antibody targeting the immune checkpoint receptor Cytotoxic T-Lymphocyte-Associated Antigen 4 (CTLA-4), and SHR-4610, which is the internal code name for axitinib, a potent and selective small-molecule tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3). By combining a checkpoint inhibitor that enhances T-cell activation with a VEGFR inhibitor that reduces tumor angiogenesis and modulates the tumor microenvironment, the therapy aims to achieve synergistic anti-tumor effects. This combination is currently being evaluated in Phase Ib/II clinical trials for patients with advanced or metastatic RCC.
- Other names
- SHR-8068 + axitinib
02
Targets
PDGFRA (Platelet-derived growth factor receptor alpha)VEGFR3 (Vascular endothelial growth factor receptor 3)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)VEGFR2 (Vascular endothelial growth factor receptor 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)PDGFRB (Platelet-derived growth factor receptor beta)
Beyond the preview
Go deeper on SHR-8068 + axitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR-8068 + axitinib.